Meta-Analysis of Spleen-Invigorating Therapy for Ischemic Stroke

OBJECTIVE To systematically evaluate the clinical efficacy and functional recovery effects of spleen-invigorating therapy in the treatment of ischemic stroke. METHODS Domestic and foreign databases were searched to obtain clinical randomized controlled trials of invigorating spleen-related therapies to treat ischemic stroke. The Rev Man5.2 software was used for Meta-analysis. RESULTS 12 randomized controlled trials with 979 patients were enrolled.Meta-analysis showed that the clinical efficacy of the spleen-invigorating therapy for ischemic stroke was significantly greater than that of Western medicine alone (CSS score)RR=1.22， 95%CI(1.09，1.37)， P<0.01. Patients' neurological deficits was improvedMD= -2.83， 95%CI(-4.20-1.46)， P<0.001 (NIHSS score)， MD=-4.17， 95%CI(-5.35-3.00)， P<0.001 (CSS score). The ADL-Barthel index score was notably ameliorated MD=9.39， 95%CI(6.50， 12.29)， P<0.001. COCLUSION Compared with conventional treatment， spleen-invigorating treatment can effectively improve clinical efficacy， recover neurological deficits caused by stroke， and improve patients' daily activities. However， due to the limitations of the research methodology and literature quality， this study still needs to be validated by more strictly designed clinical trials.